US Patent Issued to Janssen Biotech on Jan. 20 for "Treatment of non-small cell lung cancer with EGFR mutations" (Pennsylvania Inventors)

ALEXANDRIA, Va., Jan. 20 -- United States Patent no. 12,528,869, issued on Jan. 20, was assigned to Janssen Biotech Inc. (Horsham, Pa.).

"Treatment of non-small cell lung cancer with EGFR mutations" was invented by Roland Knoblauch (Doylestown, Pa.) and Sheri Moores (Wayne, Pa.).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention relates to treatment of subjects having EGFR exon 20 insertion and other uncommon EGFR mutations."

The patent was filed on Aug. 25, 2021, under Application No. 17/411,158.

*For further information, including images, charts and tables, please visit: http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l...